Double-Dye MRI could sharpen liver cancer detection

NCT ID NCT02156739

Diagnosis Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether using two contrast dyes during MRI can better tell apart benign and malignant liver lesions. About 100 patients with known or suspected liver growths will receive both gadoxetate disodium and gadobutrol before imaging. The goal is to see if the combination improves accuracy compared to using one dye alone.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: Gadoxetate disodium and gadobutrol (contrast dyes given by IV)
What this could lead to: If successful, this could lead to more accurate MRI scans for liver lesions, helping doctors tell harmless from cancerous growths without invasive biopsies.
What could go wrong: This is a small, early-stage imaging study, not a treatment trial. The results may not apply to all patients or scanners, and the contrast dyes carry a small risk of allergic reaction or kidney injury.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

100 people

The number who actually took part.

Started

Oct 2014

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with the most recent abdominal magnetic resonance (MR) study obtained within 3 months +/- 1 week * Patients with renal function (estimated glomerular filtration rate \[eGFR\] \>= 30) * Any disease type Exclusion Criteria: * Pregnant women * Patients with impaired renal function (eGFR \< 30) * Patients with surgical implants and/or metallic foreign bodies non-compatible with the MR magnet * Patients with contraindications to the use of intravenous contrast such as allergic type reactions

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatocellular carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Digestive System Diseases hepatocellular carcinoma liver cancer liver disorder metastatic malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatocellular carcinoma Liver and intrahepatic bile duct disorder Metastatic malignant neoplasm in the liver Primary malignant liver neoplasm

Double-Dye MRI could sharpen liver cancer detection

What the study statuses mean